Pfizer Covid vaccine under-5 authorization remains a focal point as U.S.health agencies weigh the broader implications for early childhood protection, balancing the urgency of preventing illness with the need to ensure long-term safety data and clear access for families, across jurisdictions and clinical settings, this alignment aims to support informed choices for families considering vaccination options.
Eli Lilly obesity pill results have recently stirred significant interest, especially with the company announcing that its groundbreaking oral medication, orforglipron, achieved an impressive average weight loss of nearly 12%, equating to about 27 pounds, during a 72-week late-stage trial.This development highlights Eli Lilly’s commitment to providing innovative solutions in the obesity treatment landscape, especially against the backdrop of competition from rivals like Novo Nordisk and their popular injectables.
Eli Lilly recently experienced a remarkable revenue surge, propelling the pharmaceutical giant to raise its 2025 forecast amid soaring demand for its flagship diabetes and obesity medications.With the successful sales increase of Mounjaro, bringing in approximately $5.2 billion and a staggering 68% year-over-year growth, Eli Lilly has set itself up for a promising future.
In a significant move to bolster its position in the healthcare technology sector, Doximity has acquired Pathway Medical for $63 million, reinforcing its commitment to enhancing AI-powered solutions for doctors.This acquisition, announced on August 7, 2025, aligns with Doximity’s mission to provide healthcare professionals with cutting-edge tools for medical inquiry and decision-making.
Omada Health’s IPO revenue growth is a compelling highlight in the telehealth space, as the company revealed its quarterly earnings soon after going public in June.With a remarkable revenue increase of 49% in the second quarter, reaching $61 million, Omada Health stands out in its commitment to virtual care programs designed for chronic condition management.
The Pfizer earnings report for the second quarter highlights a significant rebound in the company’s financial outlook, buoyed by robust sales from its Covid products.Pfizer raised its full-year adjusted profit forecast to a range between $2.90 and $3.10 per share, reflecting confidence in ongoing revenue growth driven by their diverse portfolio of medications.
Hims & Hers stock has recently faced a downturn, declining 10% after the company reported disappointing revenue figures that fell short of Wall Street expectations.In the second quarter, Hims & Hers Health saw revenue increase by an impressive 73% year over year, reaching $544.8 million; however, this was below the anticipated $552 million.
Drug pricing reform remains a crucial topic of discussion as President Donald Trump has actively urged major pharmaceutical companies to adopt measures that will lower drug prices in the United States.Under his administration, initiatives like the Trump drug policy have sought to align U.S.
Merck’s cost reduction plan is a strategic response to the anticipated revenue challenges posed by the upcoming expiration of the Keytruda patent in 2028.The pharmaceutical giant has announced its intention to cut $3 billion in expenses by the end of 2027, a move aimed at safeguarding its financial health and ensuring continued investment in drug pipeline innovations.
Sarepta Therapeutics finds itself at a tumultuous crossroads as its stock plunged over 30%, signaling significant concern over the future of its groundbreaking gene therapy, Elevidys.This drastic shift comes in the wake of alarming news linking the treatment to multiple patient deaths, prompting the FDA to evaluate the potential need for a market withdrawal.
